



**CHARITY COMMISSION  
FOR ENGLAND AND WALES**

**Trustees' Annual Report for the period**

From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	23	June	2023		22	June	2024

Charity name	Radiotherapy UK
Other names charity is known by	ACCORN Action Radiotherapy
Charity registration number	1135902

**Objectives and Activities**

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	<ol style="list-style-type: none"><li><b>To promote, support and encourage research into radiotherapy, radiobiology and allied subjects, and the dissemination of the useful results of such research by such actions as:</b><ol style="list-style-type: none"><li>Promoting and facilitating multidisciplinary collaboration between researchers and practitioners in radiotherapy and its allied subjects</li><li>Informing patients and the public about practice and research in radiotherapy and its allied subjects, and engaging patients and the public in the development of research projects</li><li>Awarding grants as appropriate</li></ol></li><li><b>To advance and benefit the practice of radiotherapy and its allied subjects to relieve sickness and preserve good health by such actions as:</b><ol style="list-style-type: none"><li>Promoting and facilitating multidisciplinary networking and sharing of expertise and best practice</li><li>Promoting and encouraging the study of the science and practice of radiotherapy and its allied subjects</li><li>Promoting and facilitating increased involvement of allied professions</li><li>Facilitating development and dissemination of best practices in radiotherapy and its allied subjects</li><li>Disseminating knowledge concerning all aspects of the science and practice of radiotherapy and its allied subjects</li><li>Promoting and facilitating education and training in the research and practice of radiotherapy and its allied subjects</li></ol></li></ol>

<p><b>Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.</b></p>	<p>Para 1.17 and 1.19</p>	<p><i>1. Patient information resources</i></p> <p>We work to support patients with cancer through the provision of trusted, accessible and relevant information resources before, during and following their radiotherapy treatment. We develop Patient Information Forum (PIF) accredited resources that means patients and families can trust that what we produce is evidence-based, understandable, jargon-free, up-to-date and produced to the best possible standard.</p> <p><i>2. Advocacy and Campaigning</i></p> <p>We work in partnership with patients, academics, workforce, industry and parliamentarians to campaign for equality of access to world-class radiotherapy for all patients with cancer in the UK. We raise awareness of how harnessing technologically advanced, cost-effective radiotherapy could treat more patients, quicker.</p> <p>We are proud to be the charity partner of the <a href="#">Radiotherapy4Life</a> campaign and co-founder of the <a href="#">#CatchUpWithCancer</a> campaign. As Secretariat for the APPG-Radiotherapy we work with the Chair and Officers in organising events, meetings and ensuring all APPG regulations and requirements are met.</p> <p>Our work also has global reach through our partnership with the Global Coalition for Radiotherapy as we support other countries advocating for increased access to radiotherapy services.</p> <p><i>3. Workforce engagement and support</i></p> <p>Our work amplifies the voice of the frontline radiotherapy workforce to raise awareness of the issues faced in the delivery of services. We provide opportunities for the workforce to learn and engage with ideas, innovations and technologies that can support them in developing patient-centred care and practice. We offer an active network of radiotherapy professionals who offer peer support, education and insight. We also promote careers in radiotherapy through job listings shared daily through our platforms and website.</p> <p><i>4. General fundraising/events</i></p> <p>The charity raises funds from a variety of sources including online giving, community events, corporate partnerships, individual donations and grants. The charity was very grateful to receive support in this financial year from B-Clear, Ergea, Brainlab, Elekta, Varian-Siemens-Healthineers, FlenHealth, Amethyst, AstraZeneca, Price-Jones, Accuray and Broyst Foundation.</p> <p><i>5. Research and Data</i></p> <p>The charity delivers analysis on publicly available data such as waiting-times for cancer treatment and produces evidence-based reports and research to better understand how radiotherapy services are currently being delivered and what needs to change to improve patient outcomes and</p>
--	---------------------------	--

		experience.
4	Para 1.18	<p>Radiotherapy UK has had regard to the guidance issued by the Charity Commission on public benefit.</p> <p>Radiotherapy UK is committed to making available to the public, information regarding radiotherapy treatment and its benefits, providing opportunities for radiotherapy professionals to share information as well as campaign for better funding for radiotherapy treatment in the UK.</p>

### Additional information (optional)

You may choose to include further statements where relevant about:

Contribution made by volunteers	Para 1.38	Volunteers are essential to our charity's success in delivering services. We depend on them to lead our organization through the Board, and to guide our efforts via the Ambassadors network, as well as patient and clinical engagement groups.
---------------------------------	-----------	--

### Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p><u>In addition to the activities noted above</u>, the charity has achieved the following this year for the benefit of patients, professionals, and the wider community:</p> <p>Advocacy and Policy</p> <ul style="list-style-type: none"> <li>Development and delivery of landmark report from the APPG-Radiotherapy; '<a href="#">World-class Radiotherapy in the UK: Right Patient, Right Treatment, Right Time.</a>' The charity facilitated a UK-wide collaboration to deliver a 10-year vision for radiotherapy that was launched in Parliament in February 2025.</li> <li>As part of our 10-year vision work, the charity launched a patient survey to understand what patients and family members thought world-class radiotherapy would look like. We received 279 responses.</li> <li>We attended two national conferences to amplify the World-class Radiotherapy report, presenting at the OPC in London and organising a 'Big Hitter' session at UKIO in London with patients and workforce leading an engaging session.</li> <li>The charity had our first abstract poster accepted for display at ESTRO 2024. Developed in partnership with the Global Coalition for Radiotherapy, the poster highlighted the need for national and international advocacy to improve access to radiotherapy. Poster can be viewed <a href="#">here</a></li> <li>Co-ordinated <a href="#">#CatchUpWithCancer day in parliament</a> for World Cancer Day 2024. Over 20 cancer charities took part and over 60 MPs committed to working to improve how long cancer patients wait for treatment in the UK.</li> <li>Actor, writer and comedian, Stephen Fry created a video supporting our <a href="#">#CatchUpWithCancer</a> campaign, leading to an additional 100,000 signatures on the <a href="#">change.org petition</a> in one day and bringing the total amount of signatures to over</li> </ul>

		<p>600,000.</p> <ul style="list-style-type: none"><li>• In partnership with Global Coalition for Radiotherapy organised ‘Integrating Radiotherapy into Cancer Plans’ event at London Global Cancer Week.</li><li>• Development, analysis and launch of <a href="#">Equity of Access report</a> found that 22% of the total population of the UK are further than the recommended 45 minutes from their closest radiotherapy service.</li><li>• Radiotherapy UK continues to act as secretariate to the All-Party Parliamentary Group for Radiotherapy. At the end of this period, the APPG had 57 members.</li></ul> <p>Patient Information Resources</p> <ul style="list-style-type: none"><li>• Radiotherapy UK was awarded <a href="#">PIF TICK</a> accreditation to become a ‘trusted information creator’ with the UK’s only assessed quality mark for print and online health and care information</li><li>• Coproduction of first <a href="#">patient ‘virtual’ video</a> to help prepare patients for the experience of external beam radiotherapy (EBRT) for breast cancer.</li><li>• Coproduction and launch of new patient video series <a href="#">‘Understanding Gamma Knife radiotherapy.</a></li><li>• Eight group and individual meetings for participants in our 2023 and 2024 Patient Engagement Groups</li><li>• Ten patient and eleven clinical reviewers supporting our patient information resource development</li></ul> <p>Workforce Engagement</p> <ul style="list-style-type: none"><li>• Five RTUK Talks webinars, with total registrations of 843 and 1,291 views on YouTube. 2024 series launched with aim of five talks sponsored by AstraZeneca.</li><li>• Workforce Ambassadors programme re-launched with 40 ambassadors in total engaged (16 from relaunch)</li><li>• Flash Workforce Survey 2023 launched. 803 Responses (over 10% of the Radiotherapy workforce) to inform and support the advocacy work of the charity in amplifying the voice of the frontline workforce.</li><li>• Official communication channel established with radiotherapy department managers via managers network chairperson.</li></ul> <p>Communications and Awareness</p> <ul style="list-style-type: none"><li>• The charity has a high media profile with regular press coverage on national news and major print publications. This year we also reached an international audience following the news of the Princess of Wales’ diagnosis with our chair features in ABC News, PBS and the Washington Post. All coverage can be found <a href="#">here.</a></li></ul> <p>In line with our communications strategy, key social and media channels have developed strongly over the course of this year:</p> <ul style="list-style-type: none"><li>• <b>LinkedIn:</b> 75.6% follower growth from 3,732 to</li></ul>
--	--	---

		6,554. <ul style="list-style-type: none"> <li>• <b>Radiotherapy UK website:</b> 40,000 new users.</li> <li>• <b>YouTube:</b> 11,015 views, 492 watch hours, 83 new subscribers (176% increase)</li> <li>• <b>Radiotherapy Daily newsletter:</b> Subscribers have grown steadily to 1,887 from 1,808. 1,498</li> <li>• <b>Instagram:</b> grown from 2,402 followers to 2,538 followers. (5.66% growth)</li> <li>• <b>Facebook:</b> grown to 2,349 followers from 2,213. (6.15% growth)</li> <li>• <b>X:</b> Analytics now a paid-for service which we cannot justify as a small charity. We are also reviewing whether we wish to continue with this platform.</li> </ul>

#### Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	N/A
Performance of fundraising activities against objectives set	Para 1.41	N/A
Other		Corporate Partnerships  The charity benefits from a number of corporate partnerships for example Varian (Siemens Healthineers) and Ergea co-sponsor the charity's Daily News bulletin. All these partnerships are agreed on a vendor neutral basis.

#### Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	<p>The Charity's total income for this financial year was £117,109 Total expenditure for this year was £162,760 leaving the charity with a year-end net deficit of £45,651</p> <p>During 2023/2024 The Charity has managed to continue its work within its limited budget by using its contacts and generous donations in kind (resources) from Price Jones Ltd.</p> <p>With the current economic constraints and cost of living crisis this is a challenging time for charity income generation. However the charity are confident that there are untapped avenues of funding available to the organisation. To support accessing these, the charity will hire a part-time fundraiser in FY24-25.</p>
Statement explaining the policy for	Para 1.22	Radiotherapy UK's policy is to provide the charity with

holding reserves stating why they are held		adequate financial stability and the means for it to meet its charitable objectives. Except for such funds as the Trustees consider prudent to maintain for the purposes of management and administration of the charity for the foreseeable future, all unrestricted funds are used to the purpose of general objects of the charity. The adequacy of the reserves is reviewed annually.
Amount of reserves held	Para 1.22	£150,624 (excluding the related party loan mentioned below)
Details of fund materially in deficit	Para 1.24	The Charity has a long-term interest-free loan from related party Price Jones Ltd which is repayable at £2,500pa. The balance at June 2024 is £15,172
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	There are no current uncertainties regarding the charity continuing as a going concern.

### Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	<p>The Charity's main source of funds for this reporting period were:</p> <ol style="list-style-type: none"> <li>1. Public Donations via online giving and community events.</li> <li>2. Corporate donations from: BClear, Ergea, Brainlab, FlenHealth, Varian Siemens-Healthineers, Amethyst, AstraZeneca, Elekta, Price Jones, Accuray.</li> <li>3. Radiotherapy4Life donation for administrative and research analysis support.</li> </ol>
Investment policy and objectives including any social investment policy adopted	Para 1.46	We do not currently hold enough reserves to warrant an investment policy.

A description of the principal risks facing the charity	Para 1.46	<p><b>Current Challenges</b></p> <ol style="list-style-type: none"> <li>1. Matching growth of charity to meet service development needs with financial constraints</li> <li>2. Strained financial environment and COL crisis creates difficult circumstances for fundraising</li> <li>3. Ensuring patients and beneficiaries engaged with services and organisational development.</li> <li>4. Developing appropriate governance structures in line with organisational growth.</li> <li>5. Changing political environment</li> <li>6. Continuing crisis in delivery of cancer services exacerbated by workforce strikes, over-bureaucracy, limiting leadership and minimal investment.</li> </ol>
---	-----------	--

Other		<p><b>Future initiatives</b></p> <p>The following are considered to be priorities for the coming year:</p> <ol style="list-style-type: none"> <li>1.Implement final year of current strategic plan and begin development of 2025 - 2028 strategy.</li> <li>2.Recruit new Board members.</li> <li>3.Development of detailed solutions following on from Radiotherapy Vision 2024</li> <li>4.Launch of new online patient information hub</li> <li>5.Recruitment of Relationship Fundraiser Manager to develop income generation avenues.</li> <li>6.Expand workforce engagement initiatives.</li> <li>7.Continue to campaign and advocate for increased access to high quality radiotherapy services across the UK</li> </ol>

## Structure, Governance and Management

<b>Description of charity's trusts:</b>		
<b>Type of governing document (trust deed, royal charter)</b>	Para 1.25	Constitution
<b>How is the charity constituted? (e.g. unincorporated association, CIO)</b>	Para 1.25	Association
<b>Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees</b>	Para 1.25	Original Trustees were nominated and elected by the ACORRN Scientific Steering Committee. New Trustees are nominated by the same process and are elected by consensus of the Board of Trustees of Radiotherapy UK.

## Reference and Administrative details

Charity name	Radiotherapy UK (previously Action Radiotherapy)
Other name the charity uses	ACORRN
Registered charity number	1135902
Charity's principal address	4 Abbotsbury House 139 Abbotsbury Road London W14 8EN

### Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Professor Patricia Price	Chair		Board of Trustees
2	Dr Christy Goldsmith	Secretary		Board of Trustees
3	Ms Tanya Levine	Treasurer		Board of Trustees
4	Dr Clive Harmer			Board of Trustees
5	Professor Philip Mayles			Board of Trustees
6				

### Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	None
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	None

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

#### Name of chief executive or names of senior staff members (Optional information)

Sarah Quinlan – Charity Director
----------------------------------




**Exemptions from disclosure**

Reason for non-disclosure of key personnel details

**Other optional information**

**Declarations**

The trustees declare that they have approved the trustees’ report above.		
Signed on behalf of the charity’s trustees		
Signature(s)		
Full name(s)	Professor Pat Price	
Position (e.g. Secretary, Chair, etc	Chair	
Date		



CHARITY COMMISSION  
FOR ENGLAND AND WALES

Radiotherapy UK

1135902

## Receipts and payments accounts

CC16a

For the period from	23.06.2023	To	22.06.2024
---------------------	------------	----	------------

### Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>					
Corporate donations	91,431	-	-	91,431	74,822
Community	23,208	-	-	23,208	21,752
Trusts & Foundations	2,470	-	-	2,470	32,000
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b> (Gross income for AR)	117,109	-	-	117,109	128,574
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	-	-	-	-	-
<b>Total receipts</b>	117,109	-	-	117,109	128,574
<b>A3 Payments</b>					
Advocacy & campaigning	11,537	-	-	11,537	2,387
Charity running costs	5,626	-	-	5,626	2,960
Communications	8,318	-	-	8,318	6,909
Contractors	60,127	-	-	60,127	82,042
Income generation	1,409	-	-	1,409	3,539
IT & development	5,734	-	-	5,734	4,335
Patient services	629	-	-	629	500
Professional fees	3,708	-	-	3,708	2,415
Promotional materials	823	-	-	823	42
Research & Data analytics	7,200	-	-	7,200	-
Salaries	53,617	-	-	53,617	3,836
Workforce services	255	-	-	255	391
Training & development	30	-	-	30	-
Loan repayment	2,500	-	-	2,500	2,500
<b>Sub total</b>	161,513	-	-	161,513	111,856
<b>A4 Asset and investment purchases, (see table)</b>					
Computer equipment	1,247	-	-	1,247	1,056
	-	-	-	-	-
<b>Sub total</b>	1,247	-	-	1,247	1,056
<b>Total payments</b>	162,760	-	-	162,760	112,912
<b>Net of receipts/(payments)</b>	45,651	-	-	45,651	15,661
<b>A5 Transfers between funds</b>	-	-	-	-	-
<b>A6 Cash funds last year end</b>	196,275	-	-	196,275	180,614
<b>Cash funds this year end</b>	150,624	-	-	150,624	196,275

## Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B1 Cash funds</b>	Bank	150,624	-	-
		-	-	-
		-	-	-
	<b>Total cash funds</b>	150,624	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK
		Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B2 Other monetary assets</b>	Details	-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
<b>B3 Investment assets</b>	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
<b>B4 Assets retained for the charity's own use</b>	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
<b>B5 Liabilities</b>	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
	Loan due to Professor Pat Price Limited		15,172	
			-	
			-	
			-	
			-	
Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval	

## Trial Balance

Radiotherapy UK

As at 22 June 2024

Cash Basis

Account Code	Account	Account Type
208	Online Platforms: Amazon	Sales
218	Events: Charity Appeals (e.g. Xmas)	Sales
226	Corporate Donations	Sales
227	Community	Sales
234	Online Platforms: Just Giving	Sales
236	Events: Miles4Radiotherapy	Sales
240	Online Platforms (all)	Sales
242	Sales of Product Income	Sales
244	Services	Sales
246	Online Platforms: Stripe	Sales
248	Trusts & Foundations	Sales
400	Professional fees: Accounting	Overhead
402	IT & Development: Accounts Management (Xero/QB)	Overhead
404	Advocacy & Campaigning (R4L)	Overhead
406	Professional fees: Bank Fees	Overhead
412	Charity Running Costs: Entertaining	Overhead
414	Contractors: Comms Support	Overhead
418	Contractors: Communications Officer	Overhead
424	Contractors (all)	Overhead
425	Contractors (GCR)	Overhead
426	Communications: Coordination Platform	Overhead
430	Communications: Daily News	Overhead
432	Contractors: Director	Overhead
434	Charity Running Costs: Equipment	Overhead
436	Income Generation: Events	Overhead
438	Income Generation: Design work (non campaign)	Overhead
442	Professional fees: HR/Recruitment	Overhead
446	Patient Services	Overhead
448	Professional fees: Insurance	Overhead
452	Interest Payable	Overhead
454	Contractors: Internship	Overhead
456	IT & Development	Overhead
458	IT & Development: IT Support	Overhead
464	Professional fees: Licencing	Overhead
466	IT & Development: Marketing Platform	Overhead
468	Professional fees: Memberships	Overhead
472	IT & Development: Monitoring & Evaluation Tools (Survey Monkey)	Overhead
480	Research & Data Analysis	Overhead
481	Training & Development (RTUK team)	Overhead
490	Communications: Photography/Video production	Overhead
492	Income Generation: Platform Fees	Overhead
494	Charity Running Costs: Postage	Overhead
495	Charity Running Costs: Stationery	Overhead
500	Contractors: Project Manager	Overhead
504	Promotional Materials	Overhead
522	Salaries (inc. payee pension contributions)	Overhead
523	Salaries: Employer pension contributions	Overhead
526	IT & Development: Software	Overhead
530	Charity Running Costs: Travel/Accommodation	Overhead
538	Workforce Services: Video Conference Tools	Overhead
540	IT & Development: Website Hosting	Overhead
542	IT & Development: Website Maintenance	Overhead
544	Communications: Website Design Projects	Overhead
552	Workforce Services: Other	Overhead
806	Loan Repayments: Loan from PJ Ltd	Current Liability
600	Current	Bank
602	Equals Account	Bank
606	Savings	Bank
610/1	Debtors	Current Asset

820	VAT	Current Liability
902	Opening Balance Equity	Equity
960	Retained Earnings	Equity
<b>Total</b>		

Debit - Year to date	Credit - Year to date	Category	22 Jun 2023
	0.00	Community	(35.85)
	0.00	Community	49.00
	91,430.74	Corporate Donations	(104,821.68)
	5,014.25	Community	0.00
	0.00	Community	(8,099.30)
	517.86	Community	(12,584.87)
	17,676.21	Community	(682.97)
	0.00	Community	(247.75)
	0.00	Community	(51.49)
	0.00	Community	(44.30)
	2,470.46	Trusts & Foundations	(2,000.00)
1,991.24		Professional fees	936.00
271.40		IT & development	244.80
11,537.81		Advocacy & campaigning	2,386.76
84.60		Professional fees	90.00
0.00		Charity running costs	71.40
0.00		Contractors	900.00
0.00		Contractors	2,116.00
55,655.25		Contractors	2,700.00
680.00		Contractors	0.00
292.80		Communications	221.90
5,000.00		Communications	4,287.50
3,791.71		Contractors	46,667.20
1,247.21		Charity running costs	1,056.29
1,408.55		Income generation	2,523.96
0.00		Income generation	1,040.00
600.00		Professional fees	444.00
628.60		Patient services	500.00
268.59		Professional fees	259.60
0.00		Interest payable	(0.04)
0.00		Contractors	4,383.46
22.40		IT & development	690.26
0.00		IT & development	374.37
625.56		Professional fees	650.60
1,030.34		IT & development	628.90
138.09		Professional fees	35.00
384.00		IT & development	384.00
7,200.00		Research & Data Analysis	0.00
30.00		Training & Development (RT	0.00
2,400.00		Communications	327.99
216.00		Charity running costs	251.99
332.44		Charity running costs	89.29
43.52		Charity running costs	0.00
0.00		Contractors	25,662.50
822.53		Promotional materials	42.00
51,434.64		Salaries	3,835.68
2,182.19		Salaries	0.00
4,013.94		IT & development	1,635.07
5,033.88		Charity running costs	2,460.57
235.08		Workforce services	225.50
0.00		IT & development	341.84
13.26		IT & development	35.99
625.00		Communications	1,700.00
19.48		Workforce services	150.00
2500	0.00	Loan	(17,672.00)
	46022.47	Bank	195,629.73
366.83		Bank	659.80
5.05		Bank	0.00
	0.00		(106.30)

434.50			0.00
			(147,200.71)
			(13,141.69)
163,566.49	163,131.99		(0.00)

	Data	
Category	Sum of Debit - Year to date	Sum of Credit - Year to date
Advocacy & campaigning	11,537.81	
Charity running costs	6,873.05	
Communications	8,317.80	
Community		23,208.32
Contractors	60,126.96	
Corporate Donations		91,430.74
Income generation	1,408.55	
Interest payable	0.00	
IT & development	5,735.34	
Loan	2,500.00	0.00
Patient services	628.60	
Professional fees	3,708.08	
Promotional materials	822.53	
Research & Data Analysis	7,200.00	
Salaries	53,616.83	
Training & Development (RTUK team)	30.00	
Trusts & Foundations		2,470.46
Workforce services	254.56	
<b>Total Result</b>	<b>162,760.11</b>	<b>117,109.52</b>



Client:	Prepared by:	Date:	Ref: <b>A2.2</b>
Year End:	Reviewed by:	Date:	
File Number:			

# **UNCORRECTED MISSTATEMENTS**

*Only those misstatements that are not regarded as clearly trivial should be recorded on this schedule. When considering whether a misstatement is material the auditor should consider size, nature and circumstances.*

**Final materiality:**

**Considered clearly trivial if below:**

Narrative		Extrapolated misstatements		Actual misstatements		Profit and loss	Balance sheet
		DR	CR	DR	CR		
Total of potential adjustments		-	-	-	-	-	-

## **Conclusion**

1. The client has been asked to adjust for all misstatements noted above.
2. Where the client has not adjusted for misstatements drawn to their attention, the letter of representation explains the directors' reasons for not adjusting as required by ISA 450.14.
3. None of the potential adjustments listed above are considered to be indicative of fraud.
4. None of the potential adjustments listed above individually or in total indicate that the overall strategy and audit plan need to be revised.

5.



## **Independent Examiner's Report to the Trustees of Radiotherapy UK**

I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2024.

### **Responsibilities and basis of report**

As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. The accounts do not accord with those records.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached.



Susan Redmond FCA  
DJH Limited  
Chartered Accountants  
St George's House  
56 Peter Street  
Manchester  
M2 3NQ

20<sup>th</sup> December 2024

**RADIOTHERAPY UK  
YEAR ENDED 22 JUNE 2024  
NOTES TO ACCOUNTS**

**Interest-free loan**

The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £15,172 and is repayable at £2,500 per annum beginning 1 July 2017.

**Related party transactions**

During the year there was a further £4,676 (2023: £2,462) paid to Professor Pat Price Limited. These were for general administrative costs, and costs relating to the All Party Parliamentary Group for Radiotherapy. All transactions were considered to be at arm's length.

During the year donations of £40,000 (2023:£44,083) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.